SUFU WM 2014 - Fesoterodine in the management of men with refractory overactive bladder (OAB) symptoms after surgery for bladder outlet obstruction - Session Highlights

MIAMI, FL USA (UroToday.com) - The efficacy of fesoterodine was assessed in patients with refractory OAB symptoms after treatment for BPH. This was a single-center pilot study of 18 male patients > 40 years of age who had bladder outlet obstruction, treated surgically, at least one month prior.

Primary endpoint was a change in International Prostate Symptom Score (IPSS) with secondary endpoints maximum urine flow rates and PVR. Fesoterodine significantly improved IPSS compared to baseline. Adverse events were: 3 (17%) patients had constipation, 1 (6%) with vision change, and 2 (11%) with dry mouth.

sufu xPresented by Lily C. Wang, Bilal Chughtai, Asha E. Jamzadeh, Richard K. Lee, Steven A. Kaplan, and Alexis E. Te at the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction (SUFU) Winter Meeting - February 25 - March 1, 2014 - Doral Golf Resort and Spa - Miami, Florida USA

 

Reported for UroToday.com by Diane K. Newman, DNP, FAAN, BCB-PMD

 

Conference Coverage
 
Recent data from conferences worldwide
  • 2020 Virtual Congress / September 19-21
  • 2020 BCAN Think Tank Virtual / August 7
  • 2020 Virtual Education Program / August 8-10
  • 2020 Annual Meeting / July 17-19 / EAU Virtual Program
  • SUO - AUA 2020 Summer Webcast / July 18
  • 2020 Annual Meeting / June 27-28 / AUA Live Virtual Program
  • 2020 Annual Meeting / May 29-31 / Virtual Scientific Program
  • 2020 Annual Meeting / February 13-15 / San Francisco, CA
  • 2019 Annual Meeting / December 4-6 / Washington, DC
  • 2019 Annual Meeting / October 3 - October 5 / Aarhus, Denmark
  • 2019 Annual Congress / September 27 - October 1 / Barcelona, Spain
  • 2019 Biennial Meeting / August 29-31 / Basel, Switzerland